These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cortical and striatal neurone number in Huntington's disease. Heinsen H; Strik M; Bauer M; Luther K; Ulmar G; Gangnus D; Jungkunz G; Eisenmenger W; Götz M Acta Neuropathol; 1994; 88(4):320-33. PubMed ID: 7839825 [TBL] [Abstract][Full Text] [Related]
43. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME Arch Neurol; 1992 Nov; 49(11):1161-7. PubMed ID: 1444883 [TBL] [Abstract][Full Text] [Related]
44. Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons. Rudinskiy N; Kaneko YA; Beesen AA; Gokce O; Régulier E; Déglon N; Luthi-Carter R J Neurochem; 2009 Oct; 111(2):460-72. PubMed ID: 19686238 [TBL] [Abstract][Full Text] [Related]
45. Expression pattern of apoptosis-related markers in Huntington's disease. Vis JC; Schipper E; de Boer-van Huizen RT; Verbeek MM; de Waal RM; Wesseling P; ten Donkelaar HJ; Kremer B Acta Neuropathol; 2005 Mar; 109(3):321-8. PubMed ID: 15668790 [TBL] [Abstract][Full Text] [Related]
46. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. Butterworth J; Yates CM; Reynolds GP J Neurol Sci; 1985 Feb; 67(2):161-71. PubMed ID: 2858515 [TBL] [Abstract][Full Text] [Related]
47. White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression. Novak MJ; Seunarine KK; Gibbard CR; Hobbs NZ; Scahill RI; Clark CA; Tabrizi SJ Cortex; 2014 Mar; 52():98-112. PubMed ID: 24405816 [TBL] [Abstract][Full Text] [Related]
48. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487 [TBL] [Abstract][Full Text] [Related]
49. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes. Marshall PE; Landis DM Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256 [TBL] [Abstract][Full Text] [Related]
50. Increased brain tissue sodium concentration in Huntington's Disease - a sodium imaging study at 4 T. Reetz K; Romanzetti S; Dogan I; Saß C; Werner CJ; Schiefer J; Schulz JB; Shah NJ Neuroimage; 2012 Oct; 63(1):517-24. PubMed ID: 22796981 [TBL] [Abstract][Full Text] [Related]
51. Insoluble TATA-binding protein accumulation in Huntington's disease cortex. van Roon-Mom WM; Reid SJ; Jones AL; MacDonald ME; Faull RL; Snell RG Brain Res Mol Brain Res; 2002 Dec; 109(1-2):1-10. PubMed ID: 12531510 [TBL] [Abstract][Full Text] [Related]
53. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. Ferrante RJ; Kowall NW; Beal MF; Martin JB; Bird ED; Richardson EP J Neuropathol Exp Neurol; 1987 Jan; 46(1):12-27. PubMed ID: 2947977 [TBL] [Abstract][Full Text] [Related]
54. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012 [TBL] [Abstract][Full Text] [Related]
55. Measurement of caudate nucleus area--a more accurate measurement for Huntington's disease? Wardlaw JM; Sellar RJ; Abernethy LJ Neuroradiology; 1991; 33(4):316-9. PubMed ID: 1833664 [TBL] [Abstract][Full Text] [Related]
56. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. O'Kusky JR; Nasir J; Cicchetti F; Parent A; Hayden MR Brain Res; 1999 Feb; 818(2):468-79. PubMed ID: 10082833 [TBL] [Abstract][Full Text] [Related]
57. Elevated brain iron is independent from atrophy in Huntington's Disease. Dumas EM; Versluis MJ; van den Bogaard SJ; van Osch MJ; Hart EP; van Roon-Mom WM; van Buchem MA; Webb AG; van der Grond J; Roos RA; Neuroimage; 2012 Jul; 61(3):558-64. PubMed ID: 22480728 [TBL] [Abstract][Full Text] [Related]
58. The contribution of glial cells to Huntington's disease pathogenesis. Wilton DK; Stevens B Neurobiol Dis; 2020 Sep; 143():104963. PubMed ID: 32593752 [TBL] [Abstract][Full Text] [Related]
59. PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease. Utal AK; Stopka AL; Roy M; Coleman PD Neuroscience; 1998 Oct; 86(4):1055-63. PubMed ID: 9697113 [TBL] [Abstract][Full Text] [Related]